HORIZONS trial: a step forward for primary percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Bivalirudin is an anticoagulant with a known association with reduced bleeding events.
• Existing data suggest similar ischemic event rates with bivalirudin across various acute coronary syndromes and elective percutaneous coronary intervention (PCI).

Purpose of the Study:

• To evaluate the efficacy and safety of bivalirudin compared to unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor in patients undergoing primary PCI.
• To assess the impact of bivalirudin on bleeding events, mortality, and net clinical benefit.

Main Methods:

• The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial compared bivalirudin with unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor during primary PCI.
• Outcomes assessed included major bleeding, death, reinfarction, target-vessel revascularization for ischemia, and stroke.

Main Results:

• Bivalirudin use resulted in a 40% reduction in major bleeding compared to the control group (4.9% vs. 8.3%).
• Net adverse clinical events were significantly reduced with bivalirudin (9.2% vs. 12.1%).
• Bivalirudin was associated with reduced cardiac and total mortality at both 30 days and 12 months post-procedure.

Conclusions:

• Bivalirudin is a safe and effective antithrombotic agent for patients undergoing primary PCI.
• It offers significant reductions in bleeding and mortality without compromising ischemic event rates.
• Bivalirudin represents an attractive therapeutic option in this patient population.